Insider activity increased in stocks such as Hudson Pacific Properties, NeoGenomics, and Carvana, signaling opportunities for traders and investors. The article examines who is buying, the forces driving their underlying markets, and the potential upside.

Three stocks across multiple sectors may draw the attention of investors looking for a momentum play - Oddity Tech Ltd, NeoGenomics Inc, and Comfort Systems USA Inc. These companies have seen significant share price improvements and positive analyst ratings, suggesting potential for continued upside.

The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

Pineapple is a next-generation decentralized exchange that combines AI-driven community interaction, cutting-edge trading tools, and a unique narrative-driven marketing approach to revolutionize DeFi trading and engagement.

The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.

The global gene panel market is projected to reach $11.75 billion by 2031, growing at a CAGR of 19.30% during the forecast period. The market growth is driven by advancements in genomic research, rising prevalence of genetic disorders, and growing awareness of genetic testing.

This report analyzes the global market for laboratory-developed tests (LDTs), including the impact of new FDA regulations introduced in 2024. It covers the LDT services market and the market for LDT products sold to clinical laboratories, with a focus on key segments like infectious disease and oncology.

Ratings for NeoGenomics (NASDAQ:NEO) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.5, a high estimate of $24.00, and a low estimate of $19.00. This current average reflects an increase of 2.5% from the previous average price target of $20.00. Breaking Down Analyst Ratings: A Detailed Examination In examining recent analyst actions, we gain insights into how financial experts perceive NeoGenomics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Lowers Buy $19.00 $24.00 David Westenberg Piper Sandler Raises Overweight $20.00 $18.00 Matthew Sykes Goldman Sachs Raises Buy $19.00 $17.00 Mike Matson Needham Raises Buy $24.00 $21.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeoGenomics. This offers insight into analysts' perspectives on the current state of the company. Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from ...Full story available on Benzinga.com

While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

NeoGenomics (NEO) delivered earnings and revenue surprises of 33.33% and 4.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.